Sentence examples for poor survival time from inspiring English sources

In our survival analysis, low expression of PER2 is clearly correlated with poor survival time.

Expression of P-gp in such cancers is associated with an increased likelihood of relapse, fewer remissions and a poor survival time (Willman, 1997; van den Heuvel-Eibrink et al, 2000; Dhooge et al, 2002).

At univariate analysis (Table 3), eight variables were significantly associated with poor survival time: ECOG PS 2, loss of weight >5%, haemoglobin ⩽11.5 g l−1, CEA >50 ng ml−1, the presence of peritoneal carcinomatosis, a number of metastatic sites 3 4, TTP under first-line chemotherapy ⩽6 months, and previous chemotherapy with regimens containing 5-FU alone.

NR patients (n=3) experienced early distant disease progression and poor survival times.

The Bayer compound BAY 12 9566 was withdrawn as it was associated with increased tumour growth and poor survival times in small cell lung cancer, but no other cases of these effects have been reported [ 125].

Given the relatively poor survival times associated with patients with brain tumours and the limited study numbers, it is difficult to draw conclusions regarding the impact that quantitative analysis may have on the management of such patients.

Hepatocellular carcinoma (HCC) is a worldwide problem hazard to human health, which has poor prognosis, short survival time, and is with the 3rd mortality rate within all cancers [ 1].

Kaplan-Meier survival curves demonstrated that CRC patients with high SHIP2 expression and positive distant metastasis encountered a significantly poorer survival time.

Significantly poorer survival (time to POM), independent of Gleason score, age, and preoperative PSA, was associated with nERβ2 positivity (adjusted hazard ratio adjHR=4.6, P=0.02).

In addition, we document a poorer survival time with loss of membranous expression of both these protein markers in univariate but not multivariable survival time analysis, indicating that the poor prognostic impact of CD44s and CD166 may be secondary to their association with other established prognostic criteria.

Expression of EpCAM has previously been linked to poorer survival time in several tumour types including breast cancer (Gastl et al, 2000), gallbladder tumours (Prince et al, 2008), and those of the Papilla Vateri (Scheunemann et al, 2007; Prince et al, 2008).